Guilhem Requirand

St Eloi Hospital
Montpellier, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

Journal: Translational oncology
Published: May 25, 2026

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.

Journal: Oncoimmunology
Published: July 20, 2025

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.

Journal: Theranostics
Published: August 02, 2024

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Journal: Blood neoplasia
Published: June 24, 2024

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

Journal: Frontiers in oncology
Published: August 03, 2023

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.

Journal: European journal of haematology
Published: June 06, 2023

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

Journal: Leukemia
Published: March 07, 2023

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.

Journal: Frontiers in immunology
Published: June 30, 2022

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.

Journal: Journal of personalized medicine
Published: September 02, 2021

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.

Journal: Theranostics
Published: October 13, 2020

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.

Journal: Blood advances
Published: August 20, 2020

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.

Journal: Theranostics
Published: July 08, 2018
Showing 1-12 of 20

Last Updated: 09/26/2026